127 related articles for article (PubMed ID: 19505457)
1. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
Chen RS; Jhan JY; Su YJ; Lee WT; Cheng CM; Ciou SC; Lin ST; Chuang SM; Ko JC; Lin YW
Exp Cell Res; 2009 Sep; 315(15):2658-72. PubMed ID: 19505457
[TBL] [Abstract][Full Text] [Related]
2. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
[TBL] [Abstract][Full Text] [Related]
3. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.
Su YJ; Tsai MS; Kuo YH; Chiu YF; Cheng CM; Lin ST; Lin YW
Mol Pharmacol; 2010 Apr; 77(4):633-43. PubMed ID: 20042515
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
Ko JC; Tsai MS; Kuo YH; Chiu YF; Weng SH; Su YC; Lin YW
Biochem Pharmacol; 2011 Mar; 81(5):680-90. PubMed ID: 21168393
[TBL] [Abstract][Full Text] [Related]
5. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.
Ko JC; Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Toxicol Appl Pharmacol; 2011 Sep; 255(3):327-38. PubMed ID: 21810436
[TBL] [Abstract][Full Text] [Related]
6. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Lin YW
Biochem Pharmacol; 2010 Feb; 79(4):655-64. PubMed ID: 19799875
[TBL] [Abstract][Full Text] [Related]
7. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
8. The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Ko JC; Hong JH; Wang LH; Lin YW
Exp Cell Res; 2008 May; 314(8):1881-91. PubMed ID: 18377894
[TBL] [Abstract][Full Text] [Related]
9. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
10. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.
Ko JC; Hong JH; Wang LH; Cheng CM; Ciou SC; Lin ST; Jheng MY; Lin YW
Mol Cancer Ther; 2008 Nov; 7(11):3632-41. PubMed ID: 19001445
[TBL] [Abstract][Full Text] [Related]
11. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Ko JC; Wang LH; Jhan JY; Ciou SC; Hong JH; Lin ST; Lin YW
Lung Cancer; 2009 Sep; 65(3):290-8. PubMed ID: 19157634
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
[TBL] [Abstract][Full Text] [Related]
13. Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells.
Ko JC; Wang TJ; Chang PY; Syu JJ; Chen JC; Chen CY; Jian YT; Jian YJ; Zheng HY; Chen WC; Lin YW
Biochem Pharmacol; 2015 Oct; 97(3):331-40. PubMed ID: 26212550
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
[TBL] [Abstract][Full Text] [Related]
15. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
16. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
[TBL] [Abstract][Full Text] [Related]
18. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Chen JC; Wang TJ; Zheng HY; Chen WC; Chang PY; Lin YW
Biochem Pharmacol; 2016 Apr; 105():91-100. PubMed ID: 26921637
[TBL] [Abstract][Full Text] [Related]
19. Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity.
Huang HS; Liu ZM; Ding L; Chang WC; Hsu PY; Wang SH; Chi CC; Chuang CH
J Biomed Sci; 2006 Jan; 13(1):113-25. PubMed ID: 16283431
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]